Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Byetta vs. Premixed Insulin Aspart in Type 2 Diabetes
NCT00434954Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2007
- Primary completion
- Jun 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Primary endpoint: Change in Glycosylated Hemoglobin at 26 weeks. Started Feb 2007; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00434954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00434954.